IGY Life Sciences is developing one of the first polyclonal antibodies for the treatment of COVID-19.  IGY-110 is an IgY antibody targeting the spike proteins of the coronavirus and is suitable for vulnerable populations, the elderly and immune compromised, who are at highest risk for COVID-19.  IGY-110 will be administered as a nasal spray and an enteric coated capsule.  The intranasal route of administration will deliver the antibodies directly to a key site of coronavirus entry and infection. 


The IGY Life Sciences intranasal delivery approach is supported by a recent major scientific publication in the journal Cell, where scientists from the University of North Carolina School of Medicine and the University of North Carolina Gillings School of Global Public Health found that SARS-Co-V2 infects and replicates in the nasal cavity to a greater degree and less well in cells lower down in the respiratory tract, including the lungs.  The enteric-coated capsule will be used to help reduce virus activity in and remove it from the gastrointestinal tract.

IGY-110 is currently in preclinical trials at Health Canada’s National Microbiology Lab in Winnipeg Manitoba.  IGY Lifesciences anticipates that IGY-110 will move through the preclinical phase rapidly since IgY antibodies are established with GRAS (Generally Regarded As Safe) status and complete the Investigational New Drug (IND) enabling work by early Fall.

If you are interested in learning more about the development of IGY-110 or related partnership opportunities, please contact